Anna Lueger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Lueger has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Julia Kargl
Medical University of Graz
4 shared publications - Kathrin Maitz
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
4 shared publications - Marah C. Runtsch
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
3 shared publications - Gunther Marsche
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
2 shared publications Oliver Kindler
Medical University of Graz, Graz, Austria
2 shared publicationsPaulina Valadez-Cosmes
Medical University of Graz, Graz, Austria
2 shared publications
Latest Publications
- Open Access
- 24 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (4) , eadq7307
Mitochondrial respiratory complex III sustains IL-10 production in activated macrophages and promotes tumor-mediated immune evasion
The cytokine interleukin-10 (IL-10) limits the immune response and promotes resolution of acute inflammation. Because of its immunosuppressive effects, IL-10 up-regulation is a common feature of tumor progression and metastasis. Recently, IL-10 regulation has been shown to depend on mitochondria and redox-sensitive signals. We have found that Suppressor of site III Qo Electron Leak 1.2 (S3QEL 1.2), a specific inhibitor of reactive oxygen species (ROS) production from mitochondrial complex III, and myxothiazol, a complex III inhibitor, decrease IL-10 in lipopolysaccharide (LPS)–activated macrophages. IL-10 down-regulation is likely to be mediated by suppression of c-Fos, which is a subunit of activator protein 1 (AP1), a transcription factor required for IL-10 gene expression. S3QEL 1.2 impairs IL-10 production in vivo after LPS challenge and promotes the survival of mice bearing B16F10 melanoma by lowering tumor growth. Our data identify a link between complex III–dependent ROS generation and IL-10 production in macrophages, the targeting of which could have potential in boosting antitumor immunity.
- 24 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (4) , eadq7307
Open AccessMitochondrial respiratory complex III sustains IL-10 production in activated macrophages and promotes tumor-mediated immune evasion
The cytokine interleukin-10 (IL-10) limits the immune response and promotes resolution of acute inflammation. Because of its immunosuppressive effects, IL-10 up-regulation is a common feature of tumor progression and metastasis. Recently, IL-10 regulation has been shown to depend on mitochondria and redox-sensitive signals. We have found that Suppressor of site III Qo Electron Leak 1.2 (S3QEL 1.2), a specific inhibitor of reactive oxygen species (ROS) production from mitochondrial complex III, and myxothiazol, a complex III inhibitor, decrease IL-10 in lipopolysaccharide (LPS)–activated macrophages. IL-10 down-regulation is likely to be mediated by suppression of c-Fos, which is a subunit of activator protein 1 (AP1), a transcription factor required for IL-10 gene expression. S3QEL 1.2 impairs IL-10 production in vivo after LPS challenge and promotes the survival of mice bearing B16F10 melanoma by lowering tumor growth. Our data identify a link between complex III–dependent ROS generation and IL-10 production in macrophages, the targeting of which could have potential in boosting antitumor immunity.
- Open Access
- 9 August 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (8) , 1587
Myeloperoxidase Alters Lung Cancer Cell Function to Benefit Their Survival
Myeloperoxidase (MPO) is a neutrophil-derived enzyme that has been recently associated with tumour development. However, the mechanisms by which this enzyme exerts its functions remain unclear. In this study, we investigated whether myeloperoxidase can alter the function of A549 human lung cancer cells. We observed that MPO promoted the proliferation of cancer cells and inhibited their apoptosis. Additionally, it increased the phosphorylation of AKT and ERK. MPO was rapidly bound to and internalized by A549 cells, retaining its enzymatic activity. Furthermore, MPO partially translocated into the nucleus and was detected in the chromatin-enriched fraction. Effects of MPO on cancer cell function could be reduced when MPO uptake was blocked with heparin or upon inhibition of the enzymatic activity with the MPO inhibitor 4-aminobenzoic acid hydrazide (4-ABAH). Lastly, we have shown that tumour-bearing mice treated with 4-ABAH had reduced tumour burden when compared to control mice. Our results highlight the role of MPO as a neutrophil-derived enzyme that can alter the function of lung cancer cells.
- 9 August 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (8) , 1587
Open AccessMyeloperoxidase Alters Lung Cancer Cell Function to Benefit Their Survival
Myeloperoxidase (MPO) is a neutrophil-derived enzyme that has been recently associated with tumour development. However, the mechanisms by which this enzyme exerts its functions remain unclear. In this study, we investigated whether myeloperoxidase can alter the function of A549 human lung cancer cells. We observed that MPO promoted the proliferation of cancer cells and inhibited their apoptosis. Additionally, it increased the phosphorylation of AKT and ERK. MPO was rapidly bound to and internalized by A549 cells, retaining its enzymatic activity. Furthermore, MPO partially translocated into the nucleus and was detected in the chromatin-enriched fraction. Effects of MPO on cancer cell function could be reduced when MPO uptake was blocked with heparin or upon inhibition of the enzymatic activity with the MPO inhibitor 4-aminobenzoic acid hydrazide (4-ABAH). Lastly, we have shown that tumour-bearing mice treated with 4-ABAH had reduced tumour burden when compared to control mice. Our results highlight the role of MPO as a neutrophil-derived enzyme that can alter the function of lung cancer cells.
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 50
Myeloperoxidase alters T cell function and plays an immunosuppressive role in non-small cell lung cancer
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 50
Myeloperoxidase alters T cell function and plays an immunosuppressive role in non-small cell lung cancer
- Open Access
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 53
Myeloperoxidase impacts lung cancer cells and drives tumor progression in non-small cell lung cancer
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 53
Open AccessMyeloperoxidase impacts lung cancer cells and drives tumor progression in non-small cell lung cancer